Verucerfont

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Verucerfont
Verucerfont structure.png
Clinical data
Routes of
administration
Oral
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
ECHA InfoCard 100.158.110 Edit this at Wikidata
Chemical and physical data
Formula C22H26N6O2
Molar mass 406.480 g/mol
3D model (JSmol)

Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRH-1 and CRH-2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress.

Verucerfont blocks the CRH-1 receptor, and so reduces ACTH release following chronic stress. It is under investigation as a potential treatment for alcoholism, as chronic stress is often a factor in both development of alcoholism and relapse in recovering alcoholics. It has shown promising results in animal studies but has not been tested in humans.[1]

See also[edit]

References[edit]

  1. ^ Zorrilla, Eric P.; Heilig, Markus; De Wit, Harriet; Shaham, Yavin (2013). "Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism". Drug and Alcohol Dependence. 128 (3): 175–86. doi:10.1016/j.drugalcdep.2012.12.017. PMC 3596012Freely accessible. PMID 23294766.